Systematic Review and Meta-analysis on the Effects of Thiopurines on Birth Outcomes from Female and Male Patients with Inflammatory Bowel Disease
Authors:
- Sveta ShahSSSveta Shah
- Fernando S. VelayosFVFernando S. Velayos
- Uma MahadevanUMUma Mahadevan
- Adam S. CheifetzACAdam S. Cheifetz
- 1 January 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (1) , 15-22
Abstract
Inflammatory bowel disease (IBD) affects people during their prime reproductive years. The thiopurines (6-mercaptopurine and azathioprine), commonly used for induction and maintenance of remission, are U.S. Food and Drug Administration (FDA) pregnancy category D, raising concern for fetal risk. We performed a systematic review and meta-analysis to evaluate the effects of thiopurine exposure during pregnancy or at the time of conception on three measures of fetal risk in women and men with IBD. A systematic search of PubMed and Web of Science using a combination of Mesh and text terms was performed to identify studies reporting birth outcomes from IBD women and men exposed to thiopurines within 3 months of conception and/or during pregnancy. A meta-analysis was performed using the random effects model to pool estimates and report odds ratio (OR) for three outcomes in women: low birth weight (LBW), preterm birth, and congenital abnormalities and one in men: congenital abnormalities. In women with IBD exposed to thiopurines, the pooled ORs for LBW, preterm birth, and congenital abnormalities were 1.01 (95% confidence interval [CI] 0.96, 1.06), 1.67 (95% CI 1.26, 2.20), and 1.45 (95% CI 0.99, 2.13), respectively. In men, the pooled OR for congenital abnormality was 1.87 (95% CI 0.67, 5.25). Thiopurine exposure in women with IBD was not associated with LBW or congenital abnormalities, but was associated with preterm birth. Exposure in men at the time of conception was not associated with congenital abnormalities.Keywords
This publication has 60 references indexed in Scilit:
- Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitisInflammatory Bowel Diseases, 2011
- Pregnancy and IBD treatment: This challenging interplay from a patients' perspectiveJournal of Crohn's and Colitis, 2010
- Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitisGut, 2005
- A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on AzathioprineGastroenterology, 2005
- Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following yearAlimentary Pharmacology & Therapeutics, 2004
- Azathioprine, mercaptopurine and birth outcome: a population‐based cohort studyAlimentary Pharmacology & Therapeutics, 2003
- Azathioprine or methotrexate in the treatment of patients with steroid‐dependent or steroid‐resistant ulcerative colitis: results of an open‐label study on efficacy and tolerability in inducing and maintaining remissionAlimentary Pharmacology & Therapeutics, 2002
- A controlled double blind study of azathioprine in the management of Crohn's disease.Gut, 1995
- Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.BMJ, 1992
- Controlled trial of azathioprine in chronic ulcerative colitis.BMJ, 1982